Clopra and Pentacarinat drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Clopra (metoclopramide hydrochloride) and Pentacarinat (pentamidine isethionate). Common drug interactions include abdominal pain among females and febrile neutropenia among males.

The phase IV clinical study analyzes what interactions people have when they take Clopra and Pentacarinat. It is created by eHealthMe based on reports of 43 people who take the same drugs from the FDA, and is updated regularly.

What is Clopra?

Clopra has active ingredients of metoclopramide hydrochloride. eHealthMe is studying from 81,430 Clopra users. Check the latest studies of Clopra.

What is Pentacarinat?

Pentacarinat has active ingredients of pentamidine isethionate. eHealthMe is studying from 1,546 Pentacarinat users. Check the latest studies of Pentacarinat.



On Jul, 26, 2026

43 people who take Clopra and Pentacarinat together, and have interactions are studied.

Clopra and Pentacarinat drug interactions.

What are the common drug interactions of Clopra and Pentacarinat, by gender? *:

female:

  1. Abdominal pain
  2. Acute respiratory distress syndrome
  3. Death
  4. Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
  5. Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
  6. Acute pulmonary oedema (sudden deposit of fluid in the lung))
  7. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  8. Alveolitis allergic (inflammation of the alveoli within the lung caused by hypersensitivity to inhaled organic dusts)
  9. Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
  10. Depressed level of consciousness

male:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  3. Acute respiratory failure
  4. Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)
  5. Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
  6. Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
  7. Nodule (a growth of abnormal tissue)
  8. Oral fungal infection
  9. Paronychia (infection in the tissues adjacent to a nail on a finger or toe)
  10. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)

What are the common drug interactions of Clopra and Pentacarinat, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Mixed liver injury

30-39:

  1. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  2. Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
  3. Influenza

40-49:

  1. Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
  2. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  3. Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
  4. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  5. Mucosal erosion (peeling off of mucous membrane)
  6. Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
  7. Acute pulmonary oedema (sudden deposit of fluid in the lung))
  8. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  9. Anaemia (lack of blood)
  10. Chills (felling of cold)

50-59:

  1. Acute respiratory distress syndrome
  2. Abdominal pain
  3. Death
  4. Febrile neutropenia (fever with reduced white blood cells)
  5. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  6. Asthenia (weakness)
  7. Folliculitis (infection of hair root)
  8. Hallucinations, mixed (sensations that appear real but are created by your mind -mixed)
  9. Phlebitis (inflammation of the walls of a vein)
  10. Staphylococcal infection (an infection with staphylococcus bacteria)

60+:

  1. Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
  2. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  3. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  4. Alveolitis allergic (inflammation of the alveoli within the lung caused by hypersensitivity to inhaled organic dusts)
  5. Depressed level of consciousness
  6. Hallucination, visual (seeing things that aren't there)
  7. Lymphopenia (an abnormally low level of lymphocytes in the blood)
  8. Myoclonus (a brief, involuntary twitching of a muscle or a group of muscles)
  9. Neutropenia (an abnormally low number of neutrophils)
  10. Toxic encephalopathy (a degenerative neurologic disorder caused by exposure to toxic substances)

What are the existing conditions these people have? *

  1. Pain: 26 people, 60.47%
  2. High Blood Pressure: 25 people, 58.14%
  3. Nausea (feeling of having an urge to vomit): 19 people, 44.19%
  4. Febrile Bone Marrow Aplasia (bone marrow greatly decreases or stops production of blood cells): 18 people, 41.86%
  5. Venoocclusive Disease (small veins in the liver are obstructed): 17 people, 39.53%
  6. Blood Disorder: 17 people, 39.53%
  7. Fungal Infection: 17 people, 39.53%
  8. Abdominal Pain Upper: 17 people, 39.53%
  9. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 11.63%
  10. Multiple Myeloma (cancer of the plasma cells): 5 people, 11.63%

* Approximation only. Some reports may have incomplete information.

Do you take Clopra and Pentacarinat?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Clopra and Pentacarinat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Clopra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pentacarinat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Clopra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pentacarinat and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on metoclopramide hydrochloride and pentamidine isethionate (the active ingredients of Clopra and Pentacarinat, respectively), and Clopra and Pentacarinat (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: